Compare MX & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MX | BDSX |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.6M | 88.3M |
| IPO Year | N/A | 2020 |
| Metric | MX | BDSX |
|---|---|---|
| Price | $3.09 | $10.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $5.75 | ★ $32.50 |
| AVG Volume (30 Days) | 309.8K | ★ 4.2M |
| Earning Date | 03-11-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $224,755,000.00 | $80,173,000.00 |
| Revenue This Year | N/A | $22.01 |
| Revenue Next Year | N/A | $26.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.62 | ★ 22.29 |
| 52 Week Low | $2.18 | $3.44 |
| 52 Week High | $5.16 | $21.60 |
| Indicator | MX | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 49.93 | 55.16 |
| Support Level | $2.78 | $9.79 |
| Resistance Level | $2.98 | $11.57 |
| Average True Range (ATR) | 0.13 | 1.47 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 19.79 | 48.51 |
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The company operates in two segments namely, Transitional Fab 3 foundry services and Standard products business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.